TY - JOUR
T1 - Real-world walking cadence in people with COPD
AU - Delgado-Ortiz, Laura
AU - Ranciati, Saverio
AU - Arbillaga-Etxarri, Ane
AU - Balcells, Eva
AU - Buekers, Joren
AU - Demeyer, Heleen
AU - Frei, Anja
AU - Gimeno-Santos, Elena
AU - Hopkinson, Nicholas S.
AU - de Jong, Corina
AU - Karlsson, Niklas
AU - Louvaris, Zafeiris
AU - Palmerini, Luca
AU - Polkey, Michael I.
AU - Puhan, Milo A.
AU - Rabinovich, Roberto A.
AU - Rodríguez Chiaradia, Diego A.
AU - Rodriguez-Roisin, Robert
AU - Toran-Montserrat, Pere
AU - Vogiatzis, Ioannis
AU - Watz, Henrik
AU - Troosters, Thierry
AU - Garcia-Aymerich, Judith
N1 - Publisher Copyright:
© The authors 2024
PY - 2024/3/1
Y1 - 2024/3/1
N2 - Introduction The clinical validity of real-world walking cadence in people with COPD is unsettled. Our objective was to assess the levels, variability and association with clinically relevant COPD characteristics and outcomes of real-world walking cadence. Methods We assessed walking cadence (steps per minute during walking bouts longer than 10 s) from 7days’ accelerometer data in 593 individuals with COPD from five European countries, and clinical and functional characteristics from validated questionnaires and standardised tests. Severe exacerbations during a 12-month follow-up were recorded from patient reports and medical registries. Results Participants were mostly male (80%) and had mean±SD age of 68±8 years, post-bronchodilator forced expiratory volume in 1 s (FEV1) of 57±19% predicted and walked 6880±3926 steps·day−1. Mean walking cadence was 88±9 steps·min−1, followed a normal distribution and was highly stable within-person (intraclass correlation coefficient 0.92, 95% CI 0.90–0.93). After adjusting for age, sex, height and number of walking bouts in fractional polynomial or linear regressions, walking cadence was positively associated with FEV1, 6-min walk distance, physical activity (steps·day−1, time in moderate-to-vigorous physical activity, vector magnitude units, walking time, intensity during locomotion), physical activity experience and health-related quality of life and negatively associated with breathlessness and depression (all p<0.05). These associations remained after further adjustment for daily steps. In negative binomial regression adjusted for multiple confounders, walking cadence related to lower number of severe exacerbations during follow-up (incidence rate ratio 0.94 per step·min−1, 95% CI 0.91–0.99, p=0.009). Conclusions Higher real-world walking cadence is associated with better COPD status and lower severe exacerbations risk, which makes it attractive as a future prognostic marker and clinical outcome.
AB - Introduction The clinical validity of real-world walking cadence in people with COPD is unsettled. Our objective was to assess the levels, variability and association with clinically relevant COPD characteristics and outcomes of real-world walking cadence. Methods We assessed walking cadence (steps per minute during walking bouts longer than 10 s) from 7days’ accelerometer data in 593 individuals with COPD from five European countries, and clinical and functional characteristics from validated questionnaires and standardised tests. Severe exacerbations during a 12-month follow-up were recorded from patient reports and medical registries. Results Participants were mostly male (80%) and had mean±SD age of 68±8 years, post-bronchodilator forced expiratory volume in 1 s (FEV1) of 57±19% predicted and walked 6880±3926 steps·day−1. Mean walking cadence was 88±9 steps·min−1, followed a normal distribution and was highly stable within-person (intraclass correlation coefficient 0.92, 95% CI 0.90–0.93). After adjusting for age, sex, height and number of walking bouts in fractional polynomial or linear regressions, walking cadence was positively associated with FEV1, 6-min walk distance, physical activity (steps·day−1, time in moderate-to-vigorous physical activity, vector magnitude units, walking time, intensity during locomotion), physical activity experience and health-related quality of life and negatively associated with breathlessness and depression (all p<0.05). These associations remained after further adjustment for daily steps. In negative binomial regression adjusted for multiple confounders, walking cadence related to lower number of severe exacerbations during follow-up (incidence rate ratio 0.94 per step·min−1, 95% CI 0.91–0.99, p=0.009). Conclusions Higher real-world walking cadence is associated with better COPD status and lower severe exacerbations risk, which makes it attractive as a future prognostic marker and clinical outcome.
KW - Adults
KW - Disease
KW - Gait speed
KW - Intensity
KW - Patterns
KW - Physical-activity
KW - Statement
KW - Stroke
UR - http://www.scopus.com/inward/record.url?scp=85187878505&partnerID=8YFLogxK
U2 - 10.1183/23120541.00673-2023
DO - 10.1183/23120541.00673-2023
M3 - Article
AN - SCOPUS:85187878505
SN - 2312-0541
VL - 10
JO - ERJ Open Research
JF - ERJ Open Research
IS - 2
M1 - 00673-2023
ER -